El seguro cubre GLP-1 para bajar de peso en 2026
A phase III clinical trial called STEP 1 (Semaglutide treatment effect in people with obesity) involving 1,961 participants with obesity found that weekly subcutaneous injections of semaglutide, in addition to lifestyle intervention, produced an average of 14.9% body weight loss compared with 2.4% in those who received placebo after 68 weeks[8]
Neves JS, Packer M, Ferreira JP (2023) Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and fight trials
Ordering through a legitimate medical platform ensures that the medication you receive is safe, genuine, and appropriate for your specific health profile
This mechanism reduces appetite and increases satiety, supporting weight loss and ongoing weight management
Importantly, Ozempic (semaglutide 1 mg) and Rybelsus are not licensed for weight management and should not be used off-label for this purpose, particularly during ongoing supply shortages
/assets/images/provider/photos/2800172.png)